Advertisement

Recent Approaches and Strategies in the Generation of Antihuman Cytomegalovirus Vaccines

  • Suresh B. Boppana
  • William J. BrittEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1119)

Abstract

The development of prophylactic and to lesser extent therapeutic vaccines for the prevention of disease associated with human cytomegalovirus (HCMV) infections has received considerable attention from biomedical researchers and pharmaceutical companies over the previous 15 years, even though attempts to produce such vaccines have been described in the literature for over 40 years. Studies of the natural history of congenital HCMV infection and infection in allograft recipients have suggested that prophylaxis of disease associated with HCMV infection could be possible, particularly in hosts at risk for more severe disease secondary to the lack of preexisting immunity. Provided a substantial understanding of immune response to HCMV together with several animal models that faithfully recapitulate aspects of human infection and immunity, investigators seem well positioned to design and test candidate vaccines. Yet more recent studies of the role of a maternal immunity in the natural history of congenital HCMV infection, including the recognition that reinfection of previously immune women by genetically distinct strains of HCMV occur in populations with a high seroprevalence, have raised several questions about the nature of protective immunity in maternal populations. This finding coupled with observations that have documented a significant incidence of damaging congenital infections in offspring of women with immunity to HCMV prior to conception has suggested that vaccine development based on conventional paradigms of adaptive immunity to viral infections may be of limited value in the prevention of damaging congenital HCMV infections. Perhaps a more achievable goal will be prophylactic vaccines to modify HCMV associated disease in allograft transplant recipients. Although recent descriptions of the results from vaccine trials have been heralded as evidence of an emerging success in the quest for a HCMV vaccine, careful analyses of these studies have also revealed that major hurdles remain to be addressed by current strategies.

Key words

Congenital CMV infection Maternal infection Maternal reinfection Adaptive immunity Animal models of CMV immunity Immune evasion Vaccine development Vaccine testing 

References

  1. 1.
    Krech U, Konjajev Z, Jung M (1971) Congenital cytomegalovirus infection in siblings from consecutive pregnancies. Helv Paediatr Acta 26:355–362PubMedGoogle Scholar
  2. 2.
    Gold E, Nankervis GA (1976) Cytomegalovirus. In: Evans AS (ed) Viral infections of humans: epidemiology and control. Plenum, New York, pp 143–161Google Scholar
  3. 3.
    Pass RF et al (1981) Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy. Infect Immun 34:166–170PubMedCentralPubMedGoogle Scholar
  4. 4.
    Stagno S et al (1982) Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol 25:563–576PubMedGoogle Scholar
  5. 5.
    Marshall GS, Stout GG (2005) Cytomegalovirus seroprevalence among women of childbearing age during a 10-year period. Am J Perinatol 22:371–376PubMedGoogle Scholar
  6. 6.
    Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276PubMedGoogle Scholar
  7. 7.
    Cannon MJ, Schmidt DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20:202–213PubMedGoogle Scholar
  8. 8.
    Hyde TB, Schmidt DS, Cannon MJ (2010) Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 20:311–326PubMedGoogle Scholar
  9. 9.
    Hutto C et al (1985) Epidemiology of cytomegalovirus infections in young children: day care vs. home care. Pediatr Infect Dis 4:149–152PubMedGoogle Scholar
  10. 10.
    Stagno S et al (1986) Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus and clinical outcome. JAMA 256:1904–1908PubMedGoogle Scholar
  11. 11.
    Adler SP (1989) Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 321:1290–1296PubMedGoogle Scholar
  12. 12.
    Seo S, Cho Y, Park J (2009) Serologic screening of pregnant Korean women for primary human cytomegalovirus infection using IgG avidiyt test. Korean J Lab Med 29:557–562PubMedGoogle Scholar
  13. 13.
    Yamamoto AY et al (2012) Early high CMV seroprevalence in pregnant women from a population with a high rate of congenital infection. Epidemiol Infect 3:1–5Google Scholar
  14. 14.
    Saraswathy TS et al (2011) Seroprevalence of cytomegalovirus infection in pregnant women and associated role in obstetric complications: a preliminary study. Southeast Asian J Trop Med Public Health 42:320–322PubMedGoogle Scholar
  15. 15.
    Akinbami AA et al (2011) Seroprevalence of cytomegalovirus antibodies amongst normal pregnant women in Nigeria. Int J Womens Health 3:423–428PubMedCentralPubMedGoogle Scholar
  16. 16.
    Hayes D, Danks M, Givas H, Jack I (1972) Cytomegalovirus in human milk. N Engl J Med 287:177PubMedGoogle Scholar
  17. 17.
    Lang DJ, Kummer JF (1975) Cytomegalovirus in semen: observations in selected populations. J Infect Dis 132:472–473PubMedGoogle Scholar
  18. 18.
    Reynolds DW et al (1973) Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 289:1–5PubMedGoogle Scholar
  19. 19.
    Alford CA, Stagno S, Pass RF (1980) Natural history of perinatal cytomegalovirus infection. In: Perinatal Infections. Excerpta Medica, Amsterdam, pp 125–147Google Scholar
  20. 20.
    Gold E, Nankervis GA (1982) Cytomegalovirus. In: Evans AS (ed) Viral infections of humans: epidemiology and control, 2nd edn. Plenum, New York, pp 167–186Google Scholar
  21. 21.
    Bate SL, Dollard SC, Cannon MJ (2010) Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis 50:1439–1447PubMedGoogle Scholar
  22. 22.
    Schopfer K, Lauber E, Krech U (1978) Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy. Arch Dis Child 53:536–539PubMedCentralPubMedGoogle Scholar
  23. 23.
    Vial P et al (1985) Serological study of cytomegalovirus, herpes simplex and rubella virus, hepatitis B and Toxoplasma gondii in 2 populations of pregnant women in Santiago, Chile. Bol Oficina Sanit Panam 99:528–538PubMedGoogle Scholar
  24. 24.
    Mussi-Pinhata MM et al (2009) Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 49:522–528PubMedCentralPubMedGoogle Scholar
  25. 25.
    Dar L et al (2008) Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J 27:841–843PubMedGoogle Scholar
  26. 26.
    Stagno S et al (1980) Breast milk and the risk of cytomegalovirus infection. N Engl J Med 302:1073–1076PubMedGoogle Scholar
  27. 27.
    Hamprecht K et al (2001) Epidemiology of transmission of cytomegalovirus from mother to preterm infants by breastfeeding. Lancet 357:513–518PubMedGoogle Scholar
  28. 28.
    Sohn YM et al (1992) Congenital cytomegalovirus infection in Korean population with very high prevalence of maternal immunity. J Korean Med Sci 7:47–51PubMedCentralPubMedGoogle Scholar
  29. 29.
    van der Sande MAB et al (2007) Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS One 2:e492PubMedCentralPubMedGoogle Scholar
  30. 30.
    Boppana SB et al (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:1366–1371PubMedGoogle Scholar
  31. 31.
    Yamamoto AY et al (2010) Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 202(3):297e1–297e8Google Scholar
  32. 32.
    Chandler SH, Handsfield HH, McDougall JK (1987) Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J Infect Dis 155:655–660PubMedGoogle Scholar
  33. 33.
    Ishibashi K et al (2007) Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin Infect Dis 45:60–67PubMedGoogle Scholar
  34. 34.
    Ross SA et al (2010) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386–389PubMedCentralPubMedGoogle Scholar
  35. 35.
    Fowler KB, Stagno S, Pass RF (1993) Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980–1990. J Infect Dis 168:552–556PubMedGoogle Scholar
  36. 36.
    Preece PM et al (1986) Congenital cytomegalovirus infection: predisposing maternal factors. J Epidemiol Community Health 40:205–209PubMedCentralPubMedGoogle Scholar
  37. 37.
    Fowler KB, Stagno S, Pass RF (1991) Rates of congenital cytomegalovirus infection based on newborn screening in two populations over an eleven year interval. Pediatr Res 29:90AGoogle Scholar
  38. 38.
    Jordan MC et al (1973) Association of cervical cytomegaloviruses with venereal disease. N Engl J Med 288:932–934PubMedGoogle Scholar
  39. 39.
    Willmott FE (1975) Cytomegalovirus in female patients attending a VD clinic. Br J Vener Dis 51:278–280PubMedCentralPubMedGoogle Scholar
  40. 40.
    Drew WL et al (1981) Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 143:188–192PubMedGoogle Scholar
  41. 41.
    Chandler SH et al (1985) The epidemiology of cytomegaloviral infection in women attending a sexually transmitted disease clinic. J Infect Dis 152:597–605PubMedGoogle Scholar
  42. 42.
    Sohn YM et al (1991) Cytomegalovirus infection in sexually active adolescents. J Infect Dis 163:460–463PubMedGoogle Scholar
  43. 43.
    Knox GE et al (1979) Comparative prevalence of subclinical cytomegalovirus and herpes simplex virus infections in the genital and urinary tracts of low income, urban females. J Infect Dis 140:419–422PubMedGoogle Scholar
  44. 44.
    Ahlfors K et al (1981) Secondary maternal cytomegalovirus infection causing symptomatic congenital infection. N Engl J Med 305:284PubMedGoogle Scholar
  45. 45.
    Stagno S et al (1982) Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl J Med 306:945–949PubMedGoogle Scholar
  46. 46.
    Ahlfors K et al (1983) Congenital cytomegalovirus infection: on the relation between type and time of maternal infection and infant’s symptoms. Scand J Infect Dis 15:129–138PubMedGoogle Scholar
  47. 47.
    Stagno S et al (1983) Congenital and perinatal cytomegaloviral infections. Semin Perinatol 7:31–42PubMedGoogle Scholar
  48. 48.
    Fowler KB et al (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667PubMedGoogle Scholar
  49. 49.
    Demmler GJ (1990) Infectious Diseases Society of America and Centers for Disease Control: summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 13:315–329Google Scholar
  50. 50.
    Boppana SB et al (1999) Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104:55–60PubMedGoogle Scholar
  51. 51.
    Ahlfors K, Ivarsson SA, Harris S (1999) Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis 31:443–457PubMedGoogle Scholar
  52. 52.
    Yamamoto AY et al (2011) Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly seropositive population. Pediatr Infect Dis J 30:1043–1046PubMedCentralPubMedGoogle Scholar
  53. 53.
    Townsend CL et al (2013) Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 56:1232–1239PubMedGoogle Scholar
  54. 54.
    Huang ES et al (1980) Molecular epidemiology of cytomegalovirus infections in women and their infants. N Engl J Med 303:958–962PubMedGoogle Scholar
  55. 55.
    Renzette N et al (2011) Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7:e1001344PubMedCentralPubMedGoogle Scholar
  56. 56.
    Ross SA et al (2011) Mixed infection and strain diversity in congenital cytomegalovirus infection. J Infect Dis 204:1003–1007PubMedCentralPubMedGoogle Scholar
  57. 57.
    Bale JF Jr et al (2001) Human cytomegalovirus a sequence and UL144 variability in strains from infected children. J Med Virol 65:90–96PubMedGoogle Scholar
  58. 58.
    Bale JF et al (1999) Cytomegalovirus transmission in child care homes. Arch Pediatr Adolesc Med 153:75–79PubMedGoogle Scholar
  59. 59.
    Chandler SH, McDougall JK (1986) Comparison of restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus. J Gen Virol 67:2179–2192PubMedGoogle Scholar
  60. 60.
    Novak Z et al (2008) Cytomegalovirus strain diversity in seropositive women. J Clin Microbiol 46:882–886PubMedCentralPubMedGoogle Scholar
  61. 61.
    Starr SE et al (1979) Impaired cellular immunity to cytomegalovirus in congenitally infected children and their mothers. J Infect Dis 140:500–505PubMedGoogle Scholar
  62. 62.
    Gehrz RC et al (1977) Specific cell-mediated immune defect in active cytomegalovirus infection of young children and their mothers. Lancet 2:844–847PubMedGoogle Scholar
  63. 63.
    Miles DJ et al (2008) CD4(+) T cell responses to cytomegalovirus in early life: a prospective birth cohort study. J Infect Dis 197:658–662PubMedGoogle Scholar
  64. 64.
    Tu W et al (2004) Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 172:3260–3267PubMedGoogle Scholar
  65. 65.
    Marchant A et al (2003) Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest 111:1747–1755PubMedCentralPubMedGoogle Scholar
  66. 66.
    Wang C et al (2011) Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 52:e11–13PubMedGoogle Scholar
  67. 67.
    Boppana SB, Britt WJ (1995) Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115–1121PubMedGoogle Scholar
  68. 68.
    Britt WJ et al (1990) An immunodominant linear epitope on the major envelope glcoprotein complex (gB) of human cytomegalovirus, In: VIII international congress of virology, BerlinGoogle Scholar
  69. 69.
    Fouts AE et al (2012) Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86:7444–7447PubMedCentralPubMedGoogle Scholar
  70. 70.
    Nigro G et al (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362PubMedGoogle Scholar
  71. 71.
    Visentin S et al (2012) Early pregnancy cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis 55:497–503PubMedGoogle Scholar
  72. 72.
    Maidji E et al (2006) Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 168:1210–1226PubMedCentralPubMedGoogle Scholar
  73. 73.
    Pereira L et al (2003) Human cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenenic bacteria and maternal immunity. J Virol 77:13301–13314PubMedCentralPubMedGoogle Scholar
  74. 74.
    Walker S et al (2007) Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFeron-CMV. Transpl Infect Dis 9:165–170PubMedGoogle Scholar
  75. 75.
    Mattes FM et al (2008) Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 8:990–999PubMedGoogle Scholar
  76. 76.
    Zanghellini F et al (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180:702–707PubMedGoogle Scholar
  77. 77.
    Hansen SG et al (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102–106PubMedCentralPubMedGoogle Scholar
  78. 78.
    Sester M et al (2002) Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 76:3748–3755PubMedCentralPubMedGoogle Scholar
  79. 79.
    Gamadia LE et al (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:2686–2692PubMedGoogle Scholar
  80. 80.
    Moss P, Khan N (2004) CD8(+) T-cell immunity to cytomegalovirus. Hum Immunol 65:456–464PubMedGoogle Scholar
  81. 81.
    Sylwester AW et al (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673–685PubMedCentralPubMedGoogle Scholar
  82. 82.
    Gyulai Z et al (2000) Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp 65, IE1-Exaon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTSs. J Infect Dis 181:1537–1546PubMedGoogle Scholar
  83. 83.
    Lilleri D et al (2007) Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 195:1062–1070PubMedGoogle Scholar
  84. 84.
    Baldanti F et al (2006) Human cytomegalovirus UL131A, UL130, and UL128 genes are highly conserved among field isolates. Arch Virol 151:1225–1233PubMedGoogle Scholar
  85. 85.
    Lissauer D et al (2011) Cytomegalovirus seropositivity dramatically alters the maternal CD8+ T cell repertoire and leads to the accumulation of highly differentiated memory cells during human pregnancy. Hum Reprod 26:3355–3365PubMedGoogle Scholar
  86. 86.
    Li CR et al (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971–1979PubMedGoogle Scholar
  87. 87.
    Reusser P et al (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380PubMedGoogle Scholar
  88. 88.
    Walter EA et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044PubMedGoogle Scholar
  89. 89.
    Rosa L et al (2007) Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 195:633–644PubMedGoogle Scholar
  90. 90.
    Schooley RT et al (1983) Association of herpes virus infection with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 308:307–313PubMedGoogle Scholar
  91. 91.
    Sester M et al (2001) Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287–1294PubMedGoogle Scholar
  92. 92.
    Reusser P et al (1999) Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 180:247–253PubMedGoogle Scholar
  93. 93.
    Pourgheysari B et al (2009) Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 43:853–861PubMedGoogle Scholar
  94. 94.
    Razonable RR (2008) Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 14:4849–4860PubMedCentralPubMedGoogle Scholar
  95. 95.
    Gallina A et al (1996) Human cytomegalovirus protein pp 65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals. J Gen Virol 77:1151–1157PubMedGoogle Scholar
  96. 96.
    Riddell SR, Greenberg PD (1994) Therapeutic reconstruction of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Top Microbiol Immunol 189:9–34PubMedGoogle Scholar
  97. 97.
    Riddell SR, Greenberg PD (2000) T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother 45:35–43PubMedGoogle Scholar
  98. 98.
    Komanduri KV et al (1998) Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:953–956PubMedGoogle Scholar
  99. 99.
    Autran B et al (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112–116PubMedGoogle Scholar
  100. 100.
    Bronke C et al (2005) Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 191:873–880PubMedGoogle Scholar
  101. 101.
    Boppana SB et al (1995) Virus specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected individuals with HCMV retinitis. J Infect Dis 171:182–185PubMedGoogle Scholar
  102. 102.
    Dylewski J, Chou S, Merigan TC (1983) Absence of detectable IgM antibody during cytomegalovirus disease in patients with AIDS [letter]. N Engl J Med 309:493PubMedGoogle Scholar
  103. 103.
    Rasmussen L et al (1994) Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis 170:673–677PubMedGoogle Scholar
  104. 104.
    Arribas JR et al (1996) Cytomegalovirus encephalitis. Ann Intern Med 125:577–587PubMedGoogle Scholar
  105. 105.
    Evans PC et al (1999) Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J Hepatol 31:913–920PubMedGoogle Scholar
  106. 106.
    Lautenschlager I et al (2006) Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 8:21–30PubMedGoogle Scholar
  107. 107.
    Myerson D, Hackman RC, Meyers JD (1984) Diagnosis of cytomegaloviral pneumonia by in situ hybridization. J Infect Dis 150:272–277PubMedGoogle Scholar
  108. 108.
    Myerson D et al (1984) Widespread presence of histologically occult cytomegalovirus. Hum Pathol 15:430–439PubMedGoogle Scholar
  109. 109.
    Schleiss MR (2006) Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J 47:65–72PubMedGoogle Scholar
  110. 110.
    Britt WJ, Boppana S (2004) Human cytomegalviurs virion proteins. Hum Immunol 65:395–402PubMedGoogle Scholar
  111. 111.
    Jonjic S et al (2008) Immune evasion of natural killer cells by viruses. Curr Opin Immunol 20:30–38PubMedCentralPubMedGoogle Scholar
  112. 112.
    Jonjic S et al (1990) Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol 64:5457–5464PubMedCentralPubMedGoogle Scholar
  113. 113.
    Jonjic S et al (1994) Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 179:1713–1717PubMedGoogle Scholar
  114. 114.
    Koszinowski UH, Reddehase MJ, Jonjic S (1991) The role of CD4 and CD8 T cells in viral infections. Curr Opin Immunol 3:471–475PubMedGoogle Scholar
  115. 115.
    Koszinowski UH et al (1987) Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes. Immunol Lett 16:185–192PubMedGoogle Scholar
  116. 116.
    Krmpotic A et al (2003) Pathogenesis of murine cytomegalovirus infection. Microbes Infect 5:1263–1277PubMedGoogle Scholar
  117. 117.
    Polic B et al (1998) Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 188:1047–1054PubMedCentralPubMedGoogle Scholar
  118. 118.
    Shanley JD (1991) Murine models of cytomegalovirus associated pneumonitis. Transplant Proc 23:S12–S16Google Scholar
  119. 119.
    Shanley JD, Biczak L, Formon SJ (1993) Acute murine cytomegalovirus infection induces lethal hepatitis. J Infect Dis 167:264–269PubMedGoogle Scholar
  120. 120.
    Koszinowski UH, Del Val M, Reddehase MJ (1990) Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol 154:189–220PubMedGoogle Scholar
  121. 121.
    Alcami A, Koszinowski UH (2000) Viral mechanisms of immune evasion. Immunol Today 21:447–455PubMedGoogle Scholar
  122. 122.
    Krmpotic A et al (2005) NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 201:211–220PubMedCentralPubMedGoogle Scholar
  123. 123.
    Zimmermann A et al (2005) A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med 201:1543–1553PubMedCentralPubMedGoogle Scholar
  124. 124.
    LoPiccolo DM et al (2003) Effective inhibition of K(b)- and D(b)-restricted antigen presentation in primary macrophages by murine cytomegalovirus. J Virol 77:301–308PubMedCentralPubMedGoogle Scholar
  125. 125.
    Lenac T et al (2006) The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med 203:1843–1850PubMedCentralPubMedGoogle Scholar
  126. 126.
    Krmpotic A et al (2001) The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med 190:1285–1296Google Scholar
  127. 127.
    Krmpotic A et al (2002) MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 3:529–535PubMedGoogle Scholar
  128. 128.
    Kavanagh DG et al (2001) The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med 194:967–978PubMedCentralPubMedGoogle Scholar
  129. 129.
    Hasan M et al (2005) Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein. J Virol 79:2920–2930PubMedCentralPubMedGoogle Scholar
  130. 130.
    Hengel H et al (1999) Cytomegaloviral control of MHC class I function in the mouse. Immunol Rev 168:167–176PubMedGoogle Scholar
  131. 131.
    Smith HR et al (2002) Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A 99:8826–8831PubMedCentralPubMedGoogle Scholar
  132. 132.
    Upton JW, Kaiser WJ, Mocarski ES (2010) Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe 7:302–313PubMedGoogle Scholar
  133. 133.
    Lisnic VJ, Krmpotic A, Jonjic S (2010) Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 14:530–539Google Scholar
  134. 134.
    Humphreys IR et al (2007) Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 204:1217–1225PubMedCentralPubMedGoogle Scholar
  135. 135.
    Reddehase MJ et al (1994) The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185–193PubMedGoogle Scholar
  136. 136.
    Mathys S et al (2003) Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation. J Infect Dis 187:988–999PubMedGoogle Scholar
  137. 137.
    Spencer JV et al (2002) Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 76:1285–1292PubMedCentralPubMedGoogle Scholar
  138. 138.
    Chang WL, Barry PA (2009) Attenuation of innate immunity by cytomegalovirus IL-10 establishes a long-term deficit of adaptive antiviral immunity. Proc Natl Acad Sci U S A 107:22647–22652Google Scholar
  139. 139.
    Mandaric S et al (2012) IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged MCMV persistence. PLoS Pathog 8:e1002846PubMedCentralPubMedGoogle Scholar
  140. 140.
    Scalzo AA et al (2007) The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 85:46–54PubMedGoogle Scholar
  141. 141.
    Jonjic S, Bubic I, Krmpotic A (2006) Innate immunity to cytomegaloviruses. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister, Norfolk, UK, pp 285–321Google Scholar
  142. 142.
    Klenovsek K et al (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–3479PubMedGoogle Scholar
  143. 143.
    Schlub TE et al (2011) Comparing the kinetics of NK cells, CD4, and CD8 T cells in murine cytomegalovirus infection. J Immunol 187:1385–1392PubMedCentralPubMedGoogle Scholar
  144. 144.
    Walton SM et al (2008) The dynamics of mouse cytomegalovirus-specific CD4 T cell responses during acute and latent infection. J Immunol 181:1128–1134PubMedGoogle Scholar
  145. 145.
    Holtappels R et al (2008) CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model. Med Microbiol Immunol 197:125–134PubMedGoogle Scholar
  146. 146.
    Cekinovic D et al (2008) Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 82:12172–12180PubMedCentralPubMedGoogle Scholar
  147. 147.
    Pavic I et al (1993) Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol 74(Pt 10):2215–2223PubMedGoogle Scholar
  148. 148.
    Scalzo AA, Yokoyama WM (2008) Cmv1 and natural killer cell responses to murine cytomegalovirus infection. Curr Top Microbiol Immunol 321:101–122PubMedGoogle Scholar
  149. 149.
    Vivier E et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44–49PubMedCentralPubMedGoogle Scholar
  150. 150.
    Rapp M et al (1993) In vivo protection studies with MCMV glycoproteins gB and gH expressed by vaccinia virus. In: Michelson S, Plotkin SA (eds) Multidisciplinary approach to understanding cytomegalovirus disease. Excerpta Medica, Amsterdam, pp 327–332Google Scholar
  151. 151.
    Reddehase MJ et al (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102–3108PubMedCentralPubMedGoogle Scholar
  152. 152.
    Del Val M et al (1991) Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 65:3641–3646PubMedCentralPubMedGoogle Scholar
  153. 153.
    Mohr CA et al (2010) A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J Virol 84:7730–7742PubMedCentralPubMedGoogle Scholar
  154. 154.
    Gonzalez Armas JC et al (1996) DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70:7921–7928PubMedCentralPubMedGoogle Scholar
  155. 155.
    Morello CS, Cranmer LD, Spector DH (2000) Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp 65). J Virol 74:3696–3708PubMedCentralPubMedGoogle Scholar
  156. 156.
    Hakki M et al (2003) Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 102:3060–3067PubMedGoogle Scholar
  157. 157.
    Slavuljica I et al (2010) Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest 120:4532–4545PubMedCentralPubMedGoogle Scholar
  158. 158.
    Farrell HE, Shellam GR (1991) Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol 72:149–156PubMedGoogle Scholar
  159. 159.
    Farroway LN et al (2005) Transmission of two Australian strains of murine cytomegalovirus (MCMV) in enclosure populations of house mice (Mus domesticus). Epidemiol Infect 133:701–710PubMedCentralPubMedGoogle Scholar
  160. 160.
    Gorman S et al (2006) Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol 87:1123–1132PubMedGoogle Scholar
  161. 161.
    Barry PA et al (2006) Nonhuman primate models of intrauterine cytomegalovirus infection. ILAR J 47:49–64PubMedGoogle Scholar
  162. 162.
    Assaf BT et al (2012) Patterns of acute rhesus cytomegalovirus (RhCMV) infection predict long-term RhCMV infection. J Virol 86:6354–6357PubMedCentralPubMedGoogle Scholar
  163. 163.
    Lockridge KM et al (1999) Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol 73:9576–9583PubMedCentralPubMedGoogle Scholar
  164. 164.
    Kaur A et al (1996) Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques. J Virol 70:7725–7733PubMedCentralPubMedGoogle Scholar
  165. 165.
    Yue Y, Zhou SS, Barry PA (2003) Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 84:3371–3379PubMedGoogle Scholar
  166. 166.
    Kaur A et al (2002) Decreased frequency of cytomegalovirus (CMV)-specific CD4+ T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia. J Virol 76:3646–3658PubMedCentralPubMedGoogle Scholar
  167. 167.
    Kaur A et al (2003) Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol 77:5749–5758PubMedCentralPubMedGoogle Scholar
  168. 168.
    Yue Y et al (2008) Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol 197:117–123PubMedGoogle Scholar
  169. 169.
    Yue Y et al (2007) Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 81:1095–1109PubMedCentralPubMedGoogle Scholar
  170. 170.
    Wussow F et al (2013) A vaccine based on rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 87:1322–1332PubMedCentralPubMedGoogle Scholar
  171. 171.
    Hansen SG et al (2009) Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15:293–299PubMedCentralPubMedGoogle Scholar
  172. 172.
    Holtappels R et al (2001) Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for pp M83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65). J Virol 75:6584–6600PubMedCentralPubMedGoogle Scholar
  173. 173.
    Podlech J et al (2000) Murine model of interstitial cytomegalovirus pneumona in syngenic bone marrow transplantation: persistence of protective pulmonary CD8-T-cell infiltrates after clearance of acute infection. J Virol 74:7496–7507PubMedCentralPubMedGoogle Scholar
  174. 174.
    Holtappels R et al (2006) CD8 T-cell-based immunotherapy of cytomegalovirus disease in the mouse model of the immunocompromised bone marrow transplantation recipient. In: Reddehase MJ (ed) Cytomegaloviruses: molecular biology and immunology. Caister, Norfolk, UK, pp 383–419Google Scholar
  175. 175.
    Scalzo AA et al (1992) The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol 149:581–589PubMedGoogle Scholar
  176. 176.
    Scalzo AA et al (1990) Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med 171:1469–1483PubMedGoogle Scholar
  177. 177.
    Brown MG et al (1999) Localization on a physical map of the NKC-linked Cmv1 locus between Ly49b and the Prp gene cluster on mouse chromosome 6. J Immunol 163:1991–1999PubMedGoogle Scholar
  178. 178.
    Webb JR, Lee SH, Vidal SM (2002) Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match. Genes Immun 3:250–262PubMedGoogle Scholar
  179. 179.
    Lee SH et al (2001) Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 28:42–45PubMedGoogle Scholar
  180. 180.
    Depatie C et al (1999) Assessment of Cmv1 candidates by genetic mapping and in vivo antibody depletion of NK cell subsets. Int Immunol 11:1541–1551PubMedGoogle Scholar
  181. 181.
    Cheng TP et al (2008) Ly49h is necessary for genetic resistance to murine cytomegalovirus. Immunogenetics 60:565–573PubMedCentralPubMedGoogle Scholar
  182. 182.
    Cooper MA, Yokoyama WM (2010) Memory-like responses of natural killer cells. Immunol Rev 235:297–305PubMedCentralPubMedGoogle Scholar
  183. 183.
    Elliott JM, Yokoyama WM (2011) Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 32:364–372PubMedCentralPubMedGoogle Scholar
  184. 184.
    Fodil-Cornu N et al (2008) Ly49h-deficient C57BL/6 mice: a new mouse cytomegalovirus-susceptible model remains resistant to unrelated pathogens controlled by the NK gene complex. J Immunol 181:6394–6405PubMedGoogle Scholar
  185. 185.
    Hadaya K et al (2008) Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant 8:2674–2683PubMedGoogle Scholar
  186. 186.
    Bacon L et al (2004) Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 173:1078–1084PubMedGoogle Scholar
  187. 187.
    Bauer S et al (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729PubMedGoogle Scholar
  188. 188.
    Chalupny NJ et al (2003) ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 305:129–135PubMedGoogle Scholar
  189. 189.
    Eagle RA et al (2006) Regulation of NKG2D ligand gene expression. Hum Immunol 67:159–169PubMedGoogle Scholar
  190. 190.
    Eagle RA et al (2009) ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol 39:3207–3216PubMedGoogle Scholar
  191. 191.
    Rolle A et al (2003) Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171:902–908PubMedGoogle Scholar
  192. 192.
    Jonjic S et al (1989) Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med 169:1199–1212PubMedGoogle Scholar
  193. 193.
    Lucin P et al (1992) Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol 66:1977–1984PubMedCentralPubMedGoogle Scholar
  194. 194.
    Holtappels R et al (1998) Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates. J Virol 72:7201–7212PubMedCentralPubMedGoogle Scholar
  195. 195.
    Reddehase MJ et al (1985) Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol 55:264–273PubMedCentralPubMedGoogle Scholar
  196. 196.
    Kurz S et al (1997) Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol 71:2980–2987PubMedCentralPubMedGoogle Scholar
  197. 197.
    Baroncelli S et al (1997) Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression. J Acquir Immune Defic Syndr Hum Retrovirol 15:5–15PubMedGoogle Scholar
  198. 198.
    Sequar G et al (2002) Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis. J Virol 76:7661–7671PubMedCentralPubMedGoogle Scholar
  199. 199.
    Reuter JD et al (2004) Systemic immune deficiency necessary for cytomegalovirus invasion of the mature brain. J Virol 78:1473–1487PubMedCentralPubMedGoogle Scholar
  200. 200.
    Woolf NK, Jaquish DV, Koehrn FJ (2007) Transplacental murine cytomegalovirus infection in the brain of SCID mice. Virol J 4:26PubMedCentralPubMedGoogle Scholar
  201. 201.
    Bia FJ et al (1983) Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis 5:177–195PubMedGoogle Scholar
  202. 202.
    Bia FJ, Miller SA, Davidson KH (1984) The guinea pig cytomegalovirus model of congenital human cytomegalovirus infection. Birth Defects 20:233–241PubMedGoogle Scholar
  203. 203.
    Griffith BP et al (1986) Inbred guinea pig model of intrauterine infection with cytomegalovirus. Am J Pathol 122:112–119PubMedCentralPubMedGoogle Scholar
  204. 204.
    Borune N et al (2001) Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guniea pig model of congenital CMV infection. J Infect Dis 183:59–64Google Scholar
  205. 205.
    Schleiss MR (2007) Comparison of vaccine strategies against congenital CMV infection in the guinea pig model. J Clin Virol 41:224–230PubMedGoogle Scholar
  206. 206.
    Harrison CJ et al (1995) Reduced congenital cytomegalovirus (CMV) infection after maternal immunization with a guinea pig CMV glycoprotein before gestational primary CMV infection in the guinea pig model. J Infect Dis 172:1212–1220PubMedGoogle Scholar
  207. 207.
    Bratcher DF et al (1995) Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 172:944–950PubMedGoogle Scholar
  208. 208.
    Chatterjee A et al (2001) Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 183:1547–1553PubMedGoogle Scholar
  209. 209.
    Woolf NK (1991) Guinea pig model of congenital CMV-induced hearing loss: a review. Transplant Proc 23:32–34PubMedGoogle Scholar
  210. 210.
    Park AH et al (2010) Development of cytomegalovirus-mediated sensorineural hearing loss in a guinea pig model. Arch Otolaryngol Head Neck Surg 136:48–53PubMedGoogle Scholar
  211. 211.
    Britt WJ, Cekinovic D, Jonjic S (2013) Murine model of neonatal cytomegalovirus infection. In: Reddehasse M (ed) Cytomegaloviruses. Cassister, LondonGoogle Scholar
  212. 212.
    Koontz T et al (2008) Altered development of the brain after focal herpesvirus infection of the central nervous system. J Exp Med 205:423–435PubMedCentralPubMedGoogle Scholar
  213. 213.
    Kosmac K et al (2013) Glucocortiocoid treatment of MCMV infected newborn mice attenuates CNS inflammation and limits deficits in cerebellar development. PLoS Pathog 9:e1003200PubMedCentralPubMedGoogle Scholar
  214. 214.
    Stagno S et al (1977) Congenital cytomegalovirus infection: occurrence in an immune population. N Engl J Med 296:1254–1258PubMedGoogle Scholar
  215. 215.
    Adler SP et al (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171:26–32PubMedGoogle Scholar
  216. 216.
    Pass RF et al (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191–1199PubMedCentralPubMedGoogle Scholar
  217. 217.
    Hansen SG et al (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523–527PubMedCentralPubMedGoogle Scholar
  218. 218.
    Wloch MK et al (2008) Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197:1634–1642PubMedCentralPubMedGoogle Scholar
  219. 219.
    Griffiths PD et al (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256–1263PubMedCentralPubMedGoogle Scholar
  220. 220.
    Bernstein DI et al (2009) Randomized, double-blind, phase I trial of alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484–493PubMedGoogle Scholar
  221. 221.
    Heineman TC et al (2006) A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193:1350–1360PubMedGoogle Scholar
  222. 222.
    La Rosa C et al (2012) Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 205:1294–1304PubMedCentralPubMedGoogle Scholar
  223. 223.
    Snydman DR (1993) Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients. Transplant Proc 25:25–26PubMedGoogle Scholar
  224. 224.
    Yeager AS et al (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98:281–287PubMedGoogle Scholar
  225. 225.
    Rubin R (2002) Clinical approach to infection in the compromised host. In: Rubin R, Young LS (eds) Infection in the organ transplant recipient. Kluwer Academic, New York, pp 573–679Google Scholar
  226. 226.
    Snydman DR et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 317:1049–1054PubMedGoogle Scholar
  227. 227.
    Nigro G, Adler SP (2011) Cytomegalovirus infections during pregnancy. Curr Opin Obstet Gynecol 23:123–128PubMedGoogle Scholar
  228. 228.
    Hedlund M et al (2009) Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 183:340–351PubMedGoogle Scholar
  229. 229.
    Iwasenko JM et al (2011) Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 203:1526–1533PubMedGoogle Scholar
  230. 230.
    La Torre R et al (2006) Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 43:994–1000PubMedGoogle Scholar
  231. 231.
    Pereira L, Maidji E (2008) Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 325:383–395PubMedGoogle Scholar
  232. 232.
    Scott GM et al (2012) Cytomegalovirus infection during pregnancy with maternofetal transmission induces a proinflammatory cytokine bias in placenta and amniotic fluid. J Infect Dis 205:1305–1310PubMedGoogle Scholar
  233. 233.
    Cui X et al (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralzing antibodies comparable to natural infection. Vaccine 26:5760–5766PubMedCentralPubMedGoogle Scholar
  234. 234.
    Gerna G et al (2008) Human cytomegalvirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells but not fibroblasts, early during primary infection. J Gen Virol 89:853–865PubMedGoogle Scholar
  235. 235.
    Lilleri D et al (2012) Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 32:1324–1331PubMedGoogle Scholar
  236. 236.
    Jacobson MA et al (2009) A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine 27:1540–1548PubMedGoogle Scholar
  237. 237.
    Boppana SB, Britt WJ (1996) Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 222:293–296PubMedGoogle Scholar
  238. 238.
    Borysiewicz LK et al (1988) Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol 18:269–275PubMedGoogle Scholar
  239. 239.
    Wills MR et al (1996) The human cytotoxic T lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp 65: frequency, specificity and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569–7579PubMedCentralPubMedGoogle Scholar
  240. 240.
    Pass RF et al (1995) A phase I trial of BIOCINE CMV gB vaccine in seronegative adults. In: Fifth international cytomegalovirus conference, Stockholm, SwedenGoogle Scholar
  241. 241.
    Sabbaj S et al (2011) Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 203:1534–1541PubMedCentralPubMedGoogle Scholar
  242. 242.
    Bubic I et al (2004) Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 78:7536–7544PubMedCentralPubMedGoogle Scholar
  243. 243.
    Crnkovic-Mertens I et al (1998) Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol 72:1377–1382PubMedCentralPubMedGoogle Scholar
  244. 244.
    Chang WL et al (2009) Human cytomegalovirus suppresses type I interferon secretion by plasmacytoid dendritic cells through its interleukin 10 homolog. Virology 390:330–337PubMedCentralPubMedGoogle Scholar
  245. 245.
    Logsdon NJ et al (2011) Design and analysis of rhesus cytomegalovirus IL-10 mutants as a model for novel vaccines against human cytomegalovirus. PLoS One 6:e28127PubMedCentralPubMedGoogle Scholar
  246. 246.
    Jones BC et al (2002) Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci U S A 99:9404–9409PubMedCentralPubMedGoogle Scholar
  247. 247.
    Stagno S et al (1982) Prevalence and importance of congenital cytomegalovirus infection in three different populations. J Pediatr 101:897–900PubMedGoogle Scholar
  248. 248.
    Adler SP et al (1996) Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infect Dis J 15:240–246PubMedGoogle Scholar
  249. 249.
    Picone O et al (2009) A 2-year study on cytomegalovirus infection during pregnancy in a French hospital. BJOC 116:818–823Google Scholar
  250. 250.
    Paya CV et al (2004) Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4:611–620PubMedGoogle Scholar
  251. 251.
    Kotton CN et al (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779–795PubMedGoogle Scholar
  252. 252.
    Asberg A et al (2009) Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 9:1205–1213PubMedGoogle Scholar
  253. 253.
    Ljungman P et al (2008) Manamagement of CMV, HHV-6, HHV-7 and Kaposi-sarcoma associated herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 42:227–240PubMedGoogle Scholar
  254. 254.
    Tomblyn M et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Biol Blood Marrow Transplant 15:1143–1238PubMedCentralPubMedGoogle Scholar
  255. 255.
    Drew WL et al (1984) Multiple infections by cytomegalovirus in patients with acquired immune deficiency syndrome: documentation by Southern blot hybridization. J Infect Dis 150:952–953PubMedGoogle Scholar
  256. 256.
    Burkhardt C et al (2009) Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J Gen Virol 90:1951–1961PubMedGoogle Scholar
  257. 257.
    Dal Monte P et al (2001) The product of human cytomegalovirus UL73 is a new polymorphic structural glycoprotein (gpUL73). J Hum Virol 4:26–34PubMedGoogle Scholar
  258. 258.
    Gnann JW et al (1988) Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol 132:239–248PubMedCentralPubMedGoogle Scholar
  259. 259.
    Rasmussen L et al (2002) The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates. J Virol 76:10841–10848PubMedCentralPubMedGoogle Scholar
  260. 260.
    Pass RF et al (2006) Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 35:216–220PubMedGoogle Scholar
  261. 261.
    Hodson EM et al (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev CD003774Google Scholar
  262. 262.
    Enders G et al (2011) Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52:244–246PubMedGoogle Scholar
  263. 263.
    Andersen H et al (1979) A prosepctive study on the incidence and significance of congenital cytomegalovirus infection. Acta Paediatr Scand 68:329–336PubMedGoogle Scholar
  264. 264.
    Larke RBP et al (1980) Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis 142:647–653PubMedGoogle Scholar
  265. 265.
    Peckham CS et al (1983) Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study. Lancet 1:1352–1355PubMedGoogle Scholar
  266. 266.
    Child SJ et al (2004) Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J Virol 78:197–205PubMedCentralPubMedGoogle Scholar
  267. 267.
    Brune W, Nevels M, Shenk T (2003) Murine cytomegalovirus m41 open reading frame encodes a Golgi-localized antiapoptotic progein. J Virol 77:11633–11643PubMedCentralPubMedGoogle Scholar
  268. 268.
    Jurak I et al (2008) Murine cytomegalovirus m38.5 protein inhibits Bax-mediated cell death. J Virol 82:4812–4822PubMedCentralPubMedGoogle Scholar
  269. 269.
    Cam M et al (2010) Cytomegaloviruses inhibit Bak- and Bax-mediated apoptosis with two separate viral proteins. Cell Death Differ 17:655–665PubMedGoogle Scholar
  270. 270.
    Skaletskaya A et al (2001) A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc Natl Acad Sci U S A 98:7829–7834PubMedCentralPubMedGoogle Scholar
  271. 271.
    Brune W et al (2001) Secreted virus-encoded proteins reflect murinr cytomegalovirus productivity in organs. J Infect Dis 184:1320–1324PubMedGoogle Scholar
  272. 272.
    Lenac T et al (2008) Murine cytomegalovirus regulation of NKG2D ligands. Med Microbiol Immunol 197:159–166PubMedGoogle Scholar
  273. 273.
    Lodoen MB et al (2004) The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med 200:1075–1081PubMedCentralPubMedGoogle Scholar
  274. 274.
    McCormick AL et al (2003) Differential function and expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death suppressors conserved in primate and rodent cytomegaloviruses. Virology 316:221–233PubMedGoogle Scholar
  275. 275.
    Chalupny NJ et al (2006) Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun 346:175–181PubMedGoogle Scholar
  276. 276.
    Fruh K, Yang Y (1999) Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11:76–81PubMedGoogle Scholar
  277. 277.
    Bubeck A et al (2002) The glycoprotein gp48 of murine cytomegalovirusL proteasome-dependent cytosolic dislocation and degradation. J Biol Chem 277:2216–2224PubMedGoogle Scholar
  278. 278.
    Vidal SM, Lanier LL (2006) NK cell recognition of moouse cytomegalovirus-infected cells. Curr Top Microbiol Immunol 298:183–206PubMedGoogle Scholar
  279. 279.
    Babic M et al (2010) Cytomegalovirus immunoevasion reveals the physiological role of “missing self” recognition in natural killer cell dependent virus control in vivo. J Exp Med 207:2663–2673PubMedCentralPubMedGoogle Scholar
  280. 280.
    Tomazin R et al (1999) Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD+ T cells. Nat Med 5:1039–1043PubMedGoogle Scholar
  281. 281.
    Jackson SE, Mason GM, Wills MR (2011) Human cytomegalovirus immunity and immune evasion. Virus Res 157:151–160PubMedGoogle Scholar
  282. 282.
    Arora N et al (2010) Cytomegalovirus viruria and DNAemia in healthy seropositive women. J Infect Dis 202:1800–1803PubMedCentralPubMedGoogle Scholar
  283. 283.
    Rivera LB et al (2002) Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics 110:762–767PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Departments of Pediatrics and MicrobiologyThe University of Alabama at BirminghamBirminghamUSA
  2. 2.Department of PediatricsUABBirminghamUSA

Personalised recommendations